Clearmind Medicine (CMND) Q3 2026 earnings summary

Executive summary

• Engaged in Phase I/IIa clinical trials for non-hallucinogenic, psychedelic-derived neuroplastogens targeting neuropsychiatric, metabolic, and addiction disorders, with a primary focus on Alcohol Use Disorder (AUD).

• Advanced clinical trial for CMND-100, with positive safety reviews and progression to higher dose cohorts and additional study parts.

• Acquired a 51% stake in Charging Robotics, expanding into intelligent EV wireless charging solutions.

Financial highlights

• Cash and cash equivalents as of July 31, 2026: $12.0 million, up from $3.9 million at October 31, 2025.

• Net loss for Q3 2026: $0.9 million, improved from $1.3 million in Q3 2025; nine-month net loss: $6.8 million, up from $3.2 million year-over-year.

• Operating expenses for Q3 2026: $2.2 million; nine months: $7.4 million.

• Finance income for Q3 2026: $1.3 million, driven by changes in warrant liabilities and short-term investments.

Outlook and guidance

• Cash position expected to provide liquidity for at least twelve months, but future capital requirements may exceed current resources depending on clinical trial progress.

• Continued dependence on external financing for ongoing operations and program advancement.